Literature DB >> 16554162

New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.

Abdessamad El Alaoui1, Nabendu Saha, Frédéric Schmidt, Claude Monneret, Jean-Claude Florent.   

Abstract

Two new glucuronide paclitaxel prodrugs have been synthesized. Linked to the 2'-OH of the drug by a carbonate function, they include a self-immolative spacer bearing an arylnitro or arylamino group between the drug and the glucuronic acid residue. Both prodrugs were well detoxified and easily cleaved in the presence of beta-D-glucuronidase with fast removal of the spacer, releasing paclitaxel. The arylamino spacer-containing prodrug, more stable than the corresponding nitro analogue, was selected for further studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554162     DOI: 10.1016/j.bmc.2006.03.002

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct.

Authors:  Su-Tang Lo; Stephan Stern; Jeffrey D Clogston; Jiwen Zheng; Pavan P Adiseshaiah; Marina Dobrovolskaia; Jongdoo Lim; Anil K Patri; Xiankai Sun; Eric E Simanek
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

2.  Diamagnetic Imaging Agents with a Modular Chemical Design for Quantitative Detection of β-Galactosidase and β-Glucuronidase Activities with CatalyCEST MRI.

Authors:  Gabriela Fernández-Cuervo; Kirsten A Tucker; Scott W Malm; Kyle M Jones; Mark D Pagel
Journal:  Bioconjug Chem       Date:  2016-10-06       Impact factor: 4.774

3.  A ring closing metathesis strategy for carbapyranosides of xylose and arabinose.

Authors:  Clayton E Mattis; David R Mootoo
Journal:  Carbohydr Res       Date:  2016-03-16       Impact factor: 2.104

4.  Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.

Authors:  Lutz F Tietze; Olaf Panknin; Birgit Krewer; Felix Major; Ingrid Schuberth
Journal:  Int J Mol Sci       Date:  2008-05-20       Impact factor: 6.208

Review 5.  Prodrug Strategies for Paclitaxel.

Authors:  Ziyuan Meng; Quanxia Lv; Jun Lu; Houzong Yao; Xiaoqing Lv; Feng Jiang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-05-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.